Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient

Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, Hartmut Goldschmidt
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2017-12-01
Saila:Diagnostics
Gaiak:
multiple myeloma
elotuzumab
lenalidomide
18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG PET/CT)
diffusion weighted imaging (DWI)
Sarrera elektronikoa:https://www.mdpi.com/2075-4418/7/4/61
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak